EUVIMEDEUVIMED entdecken
MetaanalyseSystematische Übersicht

Drug-Eluting Stent, Drug-Coated Balloon, or Plain Old Balloon Angioplasty for In-Stent Coronary Restenosis: Insights From a Mixed Treatment Comparison Meta-Analysis of Randomized Trials

M Haisum Maqsood iD, Robert S Zhang iD, Nil Rawal, Gal Sella iD, Neal S Kleiman iD, Sripal Bangalore iD

Circulation: Cardiovascular Interventions · 2025-12 · 18 (12)

DOI: 10.1161/circinterventions.125.015161 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Circulation: Cardiovascular Interventions, 2025-12. Verfasst von M Haisum Maqsood und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology (M.H.M.), DeBakey Heart and Vascular Center, Houston Methodist Hospital, TX. Hauptthemen laut MEDLINE: Drug-Eluting Stents, Coronary Restenosis, Angioplasty, Balloon, Coronary, Coated Materials, Biocompatible. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 41 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Drug-coated balloons (DCBs) are now a Food and Drug Administration-approved treatment option for the management of in-stent restenosis (ISR) based on superior outcomes compared with plain old balloon angioplasty (POBA) alone. However, the efficacy of DCB compared with drug-eluting stent (DES; repeat stenting) for ISR is uncertain, with prior studies showing inferiority of DCB. We aimed to compare the outcomes of DES, DCB, or POBA in patients with coronary ISR. METHODS: We searched PubMed, EMBASE, and clinicaltrials.gov databases (until August 1, 2025) for randomized clinical trials that compared DCB, DES, or POBA alone for ISR. Outcomes included major adverse cardiovascular events, target lesion revascularization, all-cause mortality, cardiovascular mortality, stent thrombosis, late lumen loss, and postprocedure minimum lumen diameter. RESULTS: From 18 randomized clinical trials that randomized 3820 patients with ISR, at mean follow-up of 18 months, compared with POBA, both DCB and DES were associated with reduction in major adverse cardiovascular events (odds ratio, 0.34 [95% CI, 0.24–0.50]; odds ratio, 0.37 [95% CI, 0.25–0.54]) driven by reduction in target lesion revascularization (odds ratio, 0.28 [95% CI, 0.15–0.50]; odds ratio, 0.21 [95% CI, 0.10–0.42]). DCB had a lower postprocedure minimum lumen diameter but lower late lumen loss (mean difference, −0.16 [95% CI, −0.29 to −0.04] mm) compared with DES with no difference in other clinical outcomes. CONCLUSIONS: In patients with ISR, DCB reduced major adverse cardiovascular events/target lesion revascularization compared with POBA. There was no significant difference in clinical outcomes between DCB and DES. REGISTRATION: URL: https://www.crd.york.ac.uk/PROSPERO ; Unique identifier: CRD42024598433.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug-Eluting StentsCoronary RestenosisAngioplasty, Balloon, CoronaryCoated Materials, BiocompatibleCoronary Artery DiseaseCardiac CathetersPercutaneous Coronary InterventionHumansRandomized Controlled Trials as TopicTreatment OutcomeRisk FactorsTime FactorsProsthesis DesignFemaleMaleRisk AssessmentMiddle AgedAged

Stichwörter der Autor:innen

coronary artery diseasedrug-eluting stentspercutaneous coronary intervention

Substanzen

Coated Materials, Biocompatible

Autor:innen und Institutionen

  • Department of Cardiology (M.H.M.), DeBakey Heart and Vascular Center, Houston Methodist Hospital, TX.
  • Division of Cardiology, Department of Medicine (R.S.Z.), New York Presbyterian Hospital, Weill Cornell Medicine.
  • Department of Medicine (N.R.), New York Presbyterian Hospital, Weill Cornell Medicine.
  • Section of Interventional Cardiology, Department of Cardiology (G.S., N.S.K.), DeBakey Heart and Vascular Center, Houston Methodist Hospital, TX.
  • Division of Cardiology, Department of Medicine, New York University Grossman School of Medicine (S.B.).

ORCID-Profile: M Haisum Maqsood, Robert S Zhang, Gal Sella, Neal S Kleiman, Sripal Bangalore

Zitieren

APA

Maqsood, M. H., Zhang, R. S., Rawal, N., Sella, G., Kleiman, N. S., & Bangalore, S. (2025). Drug-Eluting Stent, Drug-Coated Balloon, or Plain Old Balloon Angioplasty for In-Stent Coronary Restenosis: Insights From a Mixed Treatment Comparison Meta-Analysis of Randomized Trials. Circulation: Cardiovascular Interventions, 18(12). https://doi.org/10.1161/circinterventions.125.015161

Vancouver

Maqsood MH, Zhang RS, Rawal N, Sella G, Kleiman NS, Bangalore S. Drug-Eluting Stent, Drug-Coated Balloon, or Plain Old Balloon Angioplasty for In-Stent Coronary Restenosis: Insights From a Mixed Treatment Comparison Meta-Analysis of Randomized Trials. Circulation: Cardiovascular Interventions. 2025;18(12). doi:10.1161/circinterventions.125.015161

BibTeX
@article{Maqsood2025,
  author = {Maqsood, M Haisum and Zhang, Robert S and Rawal, Nil and Sella, Gal and Kleiman, Neal S and Bangalore, Sripal},
  title = {Drug-Eluting Stent, Drug-Coated Balloon, or Plain Old Balloon Angioplasty for In-Stent Coronary Restenosis: Insights From a Mixed Treatment Comparison Meta-Analysis of Randomized Trials},
  journal = {Circulation: Cardiovascular Interventions},
  year = {2025},
  volume = {18},
  number = {12},
  doi = {10.1161/circinterventions.125.015161}
}
Kostenlos starten →